{"id":"NCT06854601","sponsor":"Pharmasoft","briefTitle":"Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial in Three Parallel Groups to Evaluate the Effectiveness and Safety of Mexidol® Film-coated Tablets, 125 mg (LLC 'NPK PHARMASOFT', Russia) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years With Various Dosing Regimens (MEGA).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-13","primaryCompletion":"2020-07-13","completion":"2020-07-13","firstPosted":"2025-03-03","resultsPosted":"2025-08-17","lastUpdate":"2025-08-17"},"enrollment":333,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder (ADHD)","Anxiety Disorders and Symptoms"],"interventions":[{"type":"DRUG","name":"Mexidol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Mexidol + Placebo","otherNames":[]}],"arms":[{"label":"Main (Mexidol) + Control (Placebo)","type":"OTHER"},{"label":"Main (Mexidol)","type":"ACTIVE_COMPARATOR"},{"label":"Control (Placebo)","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD). This multicenter, prospective, double-blind, randomized trial included 333 children who met the diagnostic criteria established by the International Classification of Diseases (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Participants received either Mexidol or placebo for 42 days, and various efficacy and safety parameters were assessed.","primaryOutcome":{"measure":"The Average Change in the Total Score Across the \"Inattention\" and \"Hyperactivity/Impulsivity\" Subscales of the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV) After 6 Weeks of Therapy Compared to the Baseline Level.","timeFrame":"Visit 5 (after 6 weeks of therapy) compared to the baseline level (Visit 2 Day 1 = Randomization Visit)","effectByArm":[{"arm":"Main (Mexidol) + Control (Placebo)","deltaMin":25.41,"sd":null},{"arm":"Main (Mexidol)","deltaMin":23.04,"sd":null},{"arm":"Control (Placebo)","deltaMin":29.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":111},"commonTop":["Respiratory tract infection","Rhinitis","Headache","Nausea","Abdominal pain upper"]}}